14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATOS ranks #19597 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Atossa Genetics Inc. Stock Forecast NASDAQ:ATOS

$1.26 (-3.82%)

Volume: 3M

Closed: Jan 21, 2022

Hollow Logo Score: -6.954

Atossa Genetics Inc. Stock Forecast

$1.26 (-3.82%)

Volume: 3M

Closed: Jan 21, 2022

Score Hollow Logo -6.954

Atossa Genetics Inc. Company Profile

2300 Eastlake Avenue East

Seattle WA 98102



Industry: Biotechnology

Sector: Healthcare

Atossa Genetics Inc.


Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE